AZ's Tagrisso under review in EU for first-line advanced NSCLC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said EMA accepted for review a variation to the MAA for Tagrisso osimertinib

Read the full 172 word article

User Sign In